Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза III Россия

insulin glargine (HOE901); omega-3 polyunsaturated fatty acids (PUFA); placebo

A Multicenter, International Randomized, 2x2 Factorial Design Study to Evaluate the Effects of Lantus (Insulin Glargine) Versus Standard Care, and of Omega-3 Fatty Acids Versus Placebo, in Reducing Cardiovascular Morbidity and Mortality in High Risk People With Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or Early Type 2 Diabetes Mellitus: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

Номер протоколаLTS6035
ФазаФаза III
Участников по плану — во всех странах исследования12 537
Сроки01.08.2003 — 01.12.2011
Начало: 1 августа 2003Окончание: 1 декабря 2011
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00069784/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: от 50 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 12537 чел. во всех странах исследования.
  • Центров в реестре: 1 в одном городе. Список — ниже на странице.
  • Плановая дата окончания (12.2011) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возрастот 50 лет
ПолЛюбой
Здоровые добровольцынет

Главное из критериев

  • ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения

Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.

Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 22 · невключение: 20

Критерии включения

  • I1. Individuals with IFG and/or IGT, or early diabetes, as defined below.
  • Glucose tolerance status was determined by a 75 g oral glucose tolerance test (OGTT) that was performed fasting (ie, no consumption of food or beverage other than water for at least 8 hours) at the time of screening for all candidates who were not known to have diabetes. The qualifying OGTT could be obtained up to 4 weeks prior to screening provided that anti-diabetic therapy (if any) remained unchanged between the qualifying OGTT and the screening visit. Two plasma glucose values were drawn during the OGTT - a fasting value (FPG) and a value drawn two hours after the 75 g oral glucose load was administered (postprandial plasma glucose \[PPG\]).
  • \- Impaired glucose tolerance (IGT), defined as a PPG value ≥140 and <200 mg/dL (ie, ≥7.8 and <11.1 mmol/L), with a FPG <126 mg/dL (7.0 mmol/L).
  • \- Impaired fasting glucose (IFG), defined as an FPG ≥110 and <126 mg/dL (≥6.1 and <7 mmol/L), without diabetes mellitus (PPG must be <200 mg/dL \[11.1 mmol/L\]).
  • \- Early type 2 diabetes, defined as a FPG ≥126 mg/dL (7.0 mmol/L) or a PPG of ≥200 mg/dL (11.1 mmol/L), or a previous diagnosis of diabetes, and either:
  • on no pharmacological treatment (while ambulatory) for at least 10 weeks prior to screening, with screening glycated hemoglobin <150% of the upper limit of normal (ULN) for the laboratory (eg, <9% if the ULN is 6%)
  • or taking one oral antidiabetic drug (OAD) from among sulfonylureas (SU), biguanides, thiazolidinediones (TZDs), alpha-glucosidase inhibitors (AGIs), and meglitinides (MGTs) at a stable dose while ambulatory for at least 10 weeks at the time of screening (or for the 10 weeks prior to hospitalization if identified while hospitalized for a CV event), with screening glycated hemoglobin <133% of the ULN for the laboratory (eg, <8% if the ULN is 6%) if taking this medication at half-maximum dose or greater, and glycated hemoglobin <142% of the ULN for the laboratory (eg, <8.5% if the ULN is 6%) if taking this medication at less than half-maximum dose. Individuals taking combination products containing two or more OADs were not eligible.
  • I2. Men or women aged 50 years and older
  • I3. At least one of the following CV risk factors:
  • previous myocardial infarction (MI) (≥ 5 days prior to randomization)
  • previous stroke (≥ 5 days prior to randomization)
  • previous coronary, carotid or peripheral arterial revascularization
  • angina with documented ischemic changes (at least 2 mm ST segment depression on electrocardiogram during a Graded Exercise Test \[GXT\]; or with a cardiac imaging study positive for ischemia); or unstable angina with documented ischemic changes (either ST segment depression of at least 1 mm or an increase in troponin above the normal range but below the range diagnostic for acute myocardial infarction)
  • microalbuminuria or clinical albuminuria (an albumin: creatinine ratio ≥ 30 μg/mg in at least one or timed collection of urine with albumin excretion ≥20 μg/min or ≥30 mg/24 hours or total protein excretion ≥500 mg/24 hours)
  • left ventricular hypertrophy by electrocardiogram or echocardiogram
  • significant stenosis on angiography of coronary, carotid, or lower extremity arteries (ie, 50% or more stenosis)
  • ankle-brachial index < 0.9.
  • I4. Provision of signed and dated informed consent prior to any study procedures.
  • I5. Ability and willingness to complete study diaries and questionnaires.
  • I6. Demonstrated ability to use the self-glucose-monitoring device, and to self-inject insulin prior to randomization.
  • I7. A negative pregnancy test for all women of childbearing potential (ie, ovulating, pre- menopausal, and not surgically sterile) and the agreement of these women to use a reliable method of birth control to prevent pregnancy during the duration of the study .
  • I8. Willingness to discontinue prior omega-3 PUFA supplements for the duration of the study.

Критерии невключения

  • E1. Type 1 diabetes.
  • E2. Requiring ambulatory insulin treatment or uncontrolled or symptomatic hyperglycemia that is likely to require the addition of ambulatory insulin therapy or a new antidiabetic agent either before or within 2 weeks after randomization.
  • E3. Known anti-glutamic acid decarboxylase antibody (anti-GAD Ab) positivity in the past.
  • E4. Screening glycated hemoglobin ≥150% of the ULN for the laboratory (eg, ≥9% if the ULN is 6%).
  • E5. Unwillingness to inject insulin or perform self-monitoring of blood glucose.
  • E6. Nonadherence to the run-in requirement to inject placebo insulin and do capillary glucose monitoring for at least 4 days prior to randomization.
  • E7. Coronary artery bypass grafting (CABG) either planned at the time of screening, or CABG within the 4 years prior to screening - however, participants with angina, MI, or stroke since a previous CABG will be eligible for randomization, even if the last CABG was within 4 years.
  • E8. Serum creatinine >2.0 mg/dL (176 μmol/L) at screening.
  • E9. Active liver disease, or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 times ULN at screening.
  • E10. Chronic or recurrent treatment with systemic corticosteroids, or niacin treatment for hyperlipidemia.
  • E11. Heart failure of New York Heart Association (NYHA) Functional Class III or IV.
  • E12. Expected survival of <3 years for non-CV causes such as cancer.
  • E13. Any other factor likely to limit protocol compliance or reporting of adverse events (AEs).
  • E14. Unwilling or unable to discontinue TZDs.
  • E15. Simultaneous participation in any other clinical trial of an active pharmacologic agent.
  • E16. Unwillingness to permit sites to contact their primary physicians to communicate information about the study and the participant's data and treatment assignment.
  • E17. History of hypersensitivity to the investigational products.
  • E18. Previous randomization in this study.
  • E19. A prior heart transplant, or awaiting a heart transplant.
  • E20. Known infection with human immunodeficiency virus (HIV).

Источник: ClinicalTrials.gov, NCT00069784 · запись обновлена в реестре 31 января 2013.

Дизайн и результаты

ДизайнРандомизированное, открытое (без ослепления), факторное; цель — лечение
Включено участников (факт, все страны)12 537
Что измеряют — первичные конечные точки (2), вторичных — 3
  • Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI) or Nonfatal Stroke — from randomization until study cut-off date (median duration of follow-up: 6.2 years)
  • Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Revascularization Procedure or Hospitalization for Heart Failure (HF) — from randomization until study cut-off date (median duration of follow-up: 6.2 years)

Цель исследования

The primary objectives of the ORIGIN study were:

* To determine whether insulin glargine-mediated normoglycemia can reduce cardiovascular morbidity and/or mortality in people at high risk for vascular disease with either Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or early type 2 diabetes;
* To determine whether omega-3 fatty acids can reduce cardiovascular mortality in people with IFG, IGT or early type 2 diabetes.

The secondary objectives of the insulin glargine study were to determine if insulin glargine-mediated normoglycemia can reduce:

* total mortality (all causes);
* the risk of diabetic microvascular outcomes;
* the rate of progression of IGT or IFG to type 2 diabetes.

Где проходит

1 центр в 1 городе

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00069784 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.